Gold prices steady ahead of Fed decision; weekly weakness noted
SAN MATEO, Calif. -On Thursday, BeiGene , Ltd. (NASDAQ:ONC) reported better-than-expected fourth quarter results and provided an upbeat outlook for 2025, as its cancer drug Brukinsa continues to drive robust sales growth.
BeiGene’s shares edged up 0.39% in after-hours trading following the earnings release.
The global oncology company posted a Q4 loss of $0.11 per share, significantly narrower than analysts’ estimates of a $0.88 per share loss. Revenue surged 78% YoY to $1.13 billion, topping the consensus forecast of $1.05 billion.
BeiGene’s flagship drug Brukinsa generated $828 million in global sales for Q4, up 100% YoY. U.S. Brukinsa sales nearly doubled to $616 million, with the company noting it has become the market leader for new chronic lymphocytic leukemia patient starts.
"Our fourth quarter and full year results demonstrate our tremendous growth as a global oncology powerhouse, reinforced by the continued success of BRUKINSA," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.
For 2025, BeiGene projects total revenue between $4.9 billion to $5.3 billion, ahead of Wall Street’s expectation of $4.74 billion. The company also anticipates achieving positive GAAP operating income and cash flow from operations this year.
The company highlighted several pipeline milestones expected in 2025, including data readouts for key solid tumor programs and potential regulatory submissions for its BCL2 inhibitor sonrotoclax in blood cancers.
BeiGene ended 2024 with $2.64 billion in cash and investments. The company plans to change its name to BeOne Medicines Ltd., pending shareholder approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.